DUBLIN--(BUSINESS WIRE)--The "Precision Cancer Therapeutics, 2022" report has been added to ResearchAndMarkets.com's offering. The analyst has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress. The report includes statistical information for cancers by type on a global level. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers. The report also includes a list of Phase 3 precision therapies in development. Throughout the report, several market indicators, trends and barriers are discussed.
Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries. Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases. The demand for more effective and tolerable cancer treatments has led to the development of novel therapeutic agents that specifically target malignant cells. Today, advanced precision cancer therapies are available, and more are being developed each year. Although there are some older precision therapies on the market, the industry is now expanding the use of these treatments to better treat cancer victims. Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases. This report covers precision cancer therapies that do at least one of the following: Block or turn off chemical signals that tell the cancer cell to grow and divide Change proteins within the cancer cells so the cells die Stop making new blood vessels to feed the cancer cells Trigger the immune system to kill the cancer cells Carry toxins to the cancer cells to kill them, but not normal cells This report Precision Cancer Therapeutics, 2022 specifically focuses on five leading segments of precision therapies: Other precision therapies
Chapter 1: Executive Summary
Market Overview and Analysis
Causes of Cancer Growth May Shed Light on Treatment Environmental Factors, DNA, RNA
What is Precision Cancer Therapy? Trends in Research and Development of Precision Cancer Therapeutics Monoclonal Antibodies: The Leading Area of Cancer Precision Therapy Chapter 3: Precision Cancer Therapies: Monoclonal Antibodies Monoclonal Antibody Overview
Late-Stage Monoclonal Antibodies Development
Market Breakdown of Monoclonal Antibodies
Cancer Monoclonal Antibody Market by Target Cancer Monoclonal Antibody Market by Type Chapter 4: Precision Cancer Therapies: Kinase Inhibitors Kinase Inhibitor Overview
Late-Stage Kinase Inhibitors Development
Market Breakdown of Kinase Inhibitors
Cancer Kinase Inhibitor Market by Target
Cancer Kinase Inhibitor Market by Type
Chapter 5: Precision Cancer Therapies: Angiogenesis Inhibitors Angiogenesis Inhibitor Overview
Late-Stage Angiogenesis Inhibitor Phase 3 Development
Chapter 6: Precision Cancer Therapies: CAR-T Therapies Manufacturing Process for CAR-T Late-Stage CAR-T Therapies Development
Proteasome Inhibitor Overview
Chapter 8: Precision Cancer Therapies: Other Precision Therapies Other Precision Therapies Overview
mTOR Inhibitor Afinitor (everolimus)
mTOR Inhibitor Torisel (temsirolimus) Late-Stage Other Therapies Development
Chapter 9: Market Summary
Cancer: A Growing Economic Burden
Reimbursement Landscape: A Deciding Factor for Success
Chapter 10: Market Participants
Astellas Pharma U.S., Inc
For more information about this report visit https://www.researchandmarkets.com/r/kmh6vu